PTC Therapeutics, Inc. (PTCT) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
6.77
-3% vs avg
5yr avg: 6.94
30Y Low6.9·High6.9
P/FCF
9.33
-2% vs avg
5yr avg: 9.55
30Y Low9.6·High9.6
P/B Ratio
N/A
—
5yr avg: 1951.78
30Y Low1.6·High8.4
ROE
N/A
—
5yr avg: -216.7%
30Y Low-217%·High-43%
Debt/EBITDA
0.55
+0% vs avg
5yr avg: 0.55
30Y Low0.3·High0.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PTCT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
PTC Therapeutics, Inc. trades at 10.2x earnings, roughly in line with its 5-year average of 9.8x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 54%. On a free-cash-flow basis, the stock trades at 9.3x P/FCF, roughly in line with the 5-year average of 9.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.6B | $6.7B | $3.5B | $2.1B | $2.7B | $2.8B | $4.0B | $2.8B | $1.6B | $654M | $371M |
| Enterprise Value | $6.1B | $6.2B | $5.2B | $3.7B | $3.9B | $3.9B | $4.2B | $2.9B | $1.5B | $607M | $238M |
| P/E Ratio → | 10.15 | 9.76 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.79 | 3.88 | 4.30 | 2.20 | 3.92 | 5.21 | 10.58 | 9.21 | 6.04 | 3.36 | 4.49 |
| P/B Ratio | — | — | — | — | — | 1951.78 | 8.36 | 4.76 | 4.56 | 4.18 | 3.11 |
| P/FCF | 9.33 | 9.55 | — | — | — | — | — | — | — | — | — |
| P/OCF | 9.21 | 9.43 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PTCT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
PTC Therapeutics, Inc.'s enterprise value stands at 6.8x EBITDA, roughly in line with its 5-year average of 6.9x. The Healthcare sector median is 14.2x, placing the stock at a 52% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.59 | 6.40 | 3.94 | 5.61 | 7.22 | 11.14 | 9.34 | 5.76 | 3.12 | 2.88 |
| EV / EBITDA | 6.77 | 6.94 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 7.07 | 7.32 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 8.85 | — | — | — | — | — | — | — | — | — |
PTCT Profitability
Margins and return-on-capital ratios measuring operating efficiency
PTC Therapeutics, Inc. earns an operating margin of 49.5%. Operating margins have expanded from -46.9% to 49.5% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 95.9% | 92.9% | 93.0% | 93.6% | 94.0% | 95.0% | 96.0% | 95.2% | 97.6% | -42.2% |
| Operating Margin | 49.5% | 49.5% | -37.5% | -46.9% | -64.0% | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% |
| Net Profit Margin | 39.4% | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -216.7% | -81.4% | -53.2% | -50.5% | -57.2% | -68.0% |
| ROA | 29.6% | 29.6% | -20.2% | -34.8% | -30.7% | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.6% |
| ROIC | — | — | -32.2% | -39.9% | -35.0% | -31.6% | -48.8% | -39.7% | -44.9% | -100.1% | -491.7% |
| ROCE | 55.9% | 55.9% | -25.0% | -33.9% | -32.8% | -22.3% | -26.0% | -20.6% | -18.3% | -24.3% | -48.7% |
PTCT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
PTC Therapeutics, Inc. carries a Debt/EBITDA ratio of 0.5x, which is very conservative (83% below the sector average of 3.2x). The company holds a net cash position — cash of $985M exceeds total debt of $492M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 5.6x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 882.73 | 0.87 | 0.55 | 0.44 | 0.93 | 0.82 |
| Debt / EBITDA | 0.55 | 0.55 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | 750.80 | 0.44 | 0.07 | -0.21 | -0.30 | -1.12 |
| Net Debt / EBITDA | -0.55 | -0.55 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.70 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 5.58 | 5.58 | -1.17 | -4.39 | -5.47 | -5.03 | -6.15 | -18.21 | -9.20 | -5.32 | -15.96 |
Net cash position: cash ($985M) exceeds total debt ($492M)
PTCT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
PTC Therapeutics, Inc.'s current ratio of 2.35x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.02x to 2.35x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.35 | 2.35 | 2.35 | 2.02 | 1.71 | 1.87 | 4.44 | 3.30 | 1.92 | 3.04 | 5.27 |
| Quick Ratio | 2.27 | 2.27 | 2.31 | 1.97 | 1.65 | 1.84 | 4.37 | 3.22 | 1.83 | 2.90 | 5.27 |
| Cash Ratio | 2.01 | 2.01 | 1.96 | 1.45 | 1.01 | 1.52 | 3.98 | 2.91 | 1.36 | 2.33 | 4.67 |
| Asset Turnover | — | 0.59 | 0.47 | 0.49 | 0.41 | 0.28 | 0.17 | 0.19 | 0.24 | 0.50 | 0.31 |
| Inventory Turnover | 0.90 | 0.90 | 2.47 | 2.14 | 2.05 | 2.04 | 1.01 | 0.63 | 0.79 | 0.43 | — |
| Days Sales Outstanding | — | 38.30 | 71.73 | 62.59 | 81.28 | 74.85 | 67.03 | 66.03 | 93.63 | 75.85 | 110.02 |
PTCT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
PTC Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 9.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.9% | 10.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 10.7% | 10.5% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $88M | $77M | $75M | $72M | $70M | $66M | $59M | $47M | $39M | $34M |
Peer Comparison
Compare PTCT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PTCTYou | $7B | 10.2 | 6.8 | 9.3 | 95.9% | 49.5% | — | — | 0.5 |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 BMRN | $11B | 30.4 | 16.1 | 14.5 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 RARE | $3B | -4.7 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 KRYS | $10B | 50.9 | 58.2 | 54.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RYTM | $7B | -31.1 | — | — | 89.7% | -101.2% | -129.5% | -70.1% | — |
 LGND | $6B | 44.8 | 71.4 | 112.6 | 97.5% | 17.6% | 13.5% | 3.4% | 5.6 |
 PRAX | $8B | -20.9 | — | — | — | — | -45.8% | -65.0% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
PTCT — Frequently Asked Questions
Quick answers to the most common questions about buying PTCT stock.
What is PTC Therapeutics, Inc.'s P/E ratio?
PTC Therapeutics, Inc.'s current P/E ratio is 10.2x. The historical average is 9.8x. This places it at the 100th percentile of its historical range.
What is PTC Therapeutics, Inc.'s EV/EBITDA?
PTC Therapeutics, Inc.'s current EV/EBITDA is 6.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.9x.
Is PTCT stock overvalued?
Based on historical data, PTC Therapeutics, Inc. is trading at a P/E of 10.2x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are PTC Therapeutics, Inc.'s profit margins?
PTC Therapeutics, Inc. has 95.9% gross margin and 49.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does PTC Therapeutics, Inc. have?
PTC Therapeutics, Inc.'s Debt/EBITDA ratio is 0.5x, indicating low leverage. A ratio below 2x is generally considered financially healthy.